Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Understanding the Application of Real-World Evidence and Comparing Treatment Options in Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
February 27, 2025 | 3:30 PM ET
Join Michael Johnson, MD, FACS, and David Morris, MD, FACS, as they discuss the value of real-world evidence and how it can be incorporated into daily practice to support shared decision-making. This webinar will delve into key data from 2 recent head-to-head real-world analyses of androgen receptor pathway inhibitors to explore survival outcomes in metastatic castration-sensitive prostate cancer.
This educational activity is brought to you by Janssen Biotech, Inc., and is not certified for continuing medical education. The consultants have been paid an honorarium by Janssen Biotech, Inc. The speakers are presenting on behalf of Janssen and must present information in compliance with the U.S. Food and Drug Administration (FDA) requirements applicable to Janssen.
David Morris, MD, FACS
President and Co-Director of The Advanced Therapeutics Center at Urology Associates, PC, Nashville, TN
Originally from Cleveland in East Tennessee, Dr. Morris attended The Baylor School in Chattanooga, TN. He graduated Summa Cum Laude from Vanderbilt University and then earned his doctorate from Vanderbilt University School of Medicine. Dr. Morris completed his residency training at the University of Michigan in Ann Arbor, MI with a special research interest in genetics that predicts the aggressiveness of prostate and bladder cancers. He authored and co-authored multiple scientific papers throughout his training and has presented research findings at regional and national meetings. Dr. Morris has been practicing urology since 2008. In addition to being Urology Associates’ president, he is the co-director of the Advanced Therapeutics Center for prostate cancer therapies and the Clinical Research Department.
Michael Johnson, MD, FACS
Interim Division Chief, Urology, Washington University School of Medicine, St. Louis, MO
Dr. Johnson is a Professor, Interim Division Chief, Urology, and Director of the Society for Urologic Oncology Fellowship at Washington University in St. Louis, MO. He has held positions in private practice at Oregon Urology Institute and at the Brady Urological Institute at Johns Hopkins Hospital. Dr. Johnson received his undergraduate degree from Dartmouth College, his medical degree from the University of Washington, his residency at Washington University in St. Louis, MO, and his fellowship in urologic oncology at the Brady Urological Institute at Johns Hopkins Hospital.
Dr. Johnson's research experience includes funding from the National Institutes of Health to advance "big data" efforts for precision medicine in kidney cancer and prostate cancer.
Dr. Johnson has received numerous awards for his teaching and research efforts. He has authored many scientific publications, including research articles, videos of surgical techniques, and textbook chapters.
This educational activity is brought to you by Janssen Biotech, Inc., and is not certified for continuing medical education. The consultants have been paid an honorarium by Janssen Biotech, Inc. The speakers are presenting on behalf of Janssen and must present information in compliance with the U.S. Food and Drug Administration (FDA) requirements applicable to Janssen.
The full ERLEADA® (apalutamide) Prescribing Information can be found here.